SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant community buzz through its long-standing presence on the Solana network, with supporters highlighting organic growth, burned liquidity, and its inclusion on the Jupiter strict list. Investors are actively discussing its multi-year track record and utilizing meme-driven engagement to build momentum around the token's long-term potential.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is seeing increased community chatter surrounding its role as a key liquidity hub on the Base ecosystem, with investors closely watching potential catalyst events and revenue growth. Community sentiment remains mixed, as some participants express frustration with current price action while others double down on accumulation strategies in anticipation of long-term utility gains.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a high-volatility meme coin on the Solana network, with the community actively celebrating its early growth, developer accessibility, and airdrop events. Traders are focused on pushing the token past key market cap milestones while encouraging engagement through aggressive social media activity and strategic buying during dips.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing significant volatility as community members react to high trading volume and speculative price action. Discussions are heavily focused on its role as a leading Solana DEX, with many participants debating potential price targets and sharing strategies for yield farming via liquidity pools.

OpenGradient is the Network for Open Intelligence — a decentralized infrastructure network designed to host, inference, and verify AI models at scale. Rather than functioning as a standalone blockchain, OpenGradient operates as a specialized AI coprocessor: it enables applications, blockchains, and autonomous agents to outsource computationally-heavy AI tasks to a dedicated network of GPU and Trusted Execution Environment (TEE) nodes. The validator set verifies every computational proof (TEE attestation or zkML proof) at the consensus level before it is committed on-chain, enabling trustless usage of AI from any network or application.

OpenGradient

OpenGradient is gaining momentum as a newly listed token benefiting from increased trading volume and heightened public awareness. Investors are actively discussing the asset's growth potential while comparing it to other high-volatility projects following recent exchange launches.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is currently seeing intense speculative trading activity and elevated volume as investors price in hopes of a potential acquisition or partnership, specifically fueled by its ongoing relationship with Nestl. While the company continues to advance its microbiome-based pipeline, community discussion remains highly polarized between long-term holders awaiting a strategic liquidity event and traders looking to capitalize on rapid volatility and short-squeeze potential.

Roundhill ETF Trust - Roundhill Memory ETF

The DRAM ETF is trending as investors bet on a structural AI memory supercycle, viewing high-bandwidth memory (HBM) and NAND storage as critical, supply-constrained infrastructure rather than traditional commodities. Community sentiment is overwhelmingly bullish, with active discussions focusing on the massive earnings growth from the sector's oligopoly and the ETF's unique ability to capture global exposure that was previously difficult to access.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as holders discuss its transition from a niche digital asset to a phygital powerhouse, fueled by its growing retail presence in major physical stores and utility-focused developments. The community remains focused on long-term accumulation, debating the potential for future price breakthroughs while drawing comparisons to established meme coins.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging as investors highlight its unique status as the original crypto parody project dating back to 2011, effectively blending long-standing internet lore with modern on-chain momentum. The community is buzzing over its historical significance and recent whale accumulation, framing the token as a persistent cultural movement that has outlasted years of market volatility.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to the FDA lifting the clinical hold on its Phase 3 MAGNITUDE trial, signaling a key de-risking event for the company's heart disease gene therapy pipeline. The community is actively discussing the stock's significant short interest and the potential for a recovery toward previous highs as traders weigh clinical progress against broader macroeconomic volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>On Stocktwits, retail chatter jumped about 25% over the past day, with message volume going from ‘normal’ to ‘high’ levels in the time frame.&nbsp;</li><li>Earlier this month, Eastman Kodak reported its fourth-quarter (Q4) 2025 earnings results, posting quarterly revenues of $290 million, a growth of 9%.</li><li>Meanwhile, the company also reduced its annual interest expense by approximately $40 million in FY25, strengthening its balance sheet.</li></ul>Shares of Eastman Kodak Co. (KODK), or Kodak as it is commonly referred to, surged more than 12% on Friday, briefly breaching the $10-mark for the first time since June 2021.The iconic American photography company garnered significant attention among retail traders for the milestone, with some cheering the ‘Kodak’ moment.On Stocktwits, retail chatter jumped about 25% over the past day, with message volume going from ‘normal’ to ‘high’ levels in the time frame.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260327_105336760_png_30e5326fee.webp" alt="koyfin_20260327_105336760.png" width="2400" height="1240"><figcaption>KODK stock price over 5 years | Source: Koyfin</figcaption></figure><h2 class="st-heading-2">&nbsp;</h2><h2 class="st-heading-2">What’s Retail Saying?</h2>Retail sentiment around KODK shares was ‘extremely bullish’ over the past 24 hours.One user touted the share price jump as a ‘Kodak moment’, using a term from the company’s successful advertising campaign.<stembedurl>https://stocktwits.com/DocPharm/message/648774392</stembedurl>&nbsp;Another bullish user cheered the company’s share price ascending to its ‘fair value.’<stembedurl>https://stocktwits.com/Lizzie1/message/648768482</stembedurl>&nbsp;A third user commented on the company’s shares climbing in a down market, while also noting Kodak’s value and strong balance sheet.<stembedurl>https://stocktwits.com/ChicagoMan/message/648637855</stembedurl>&nbsp;A fourth user said KODK shares were ‘still cheap’ despite the company’s recent financial improvement.<stembedurl>https://stocktwits.com/ChicagoMan/message/648768307</stembedurl><h2 class="st-heading-2">&nbsp;</h2><h2 class="st-heading-2">Financial Snapshot</h2>Earlier this month, Eastman Kodak reported its fourth-quarter (Q4) 2025 earnings results, posting quarterly revenues of $290 million, a growth of 9%. The company also posted operational earnings before interest, tax, depreciation, and amortization of $22 million, an increase of 144%.Meanwhile, the company also reduced its annual interest expense by approximately $40 million in FY25, with management adding that Kodak now has a “stronger balance sheet than we’ve had in years.” The company had a cash balance of $337 million as of Dec. 31, 2025, an increase of $136 million from Dec. 31, 2024, with management noting that the company now had more cash than debt.<a href="https://stocktwits.com/symbol/KODK">KODK stock</a> has risen more than 50% in the past year.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/wyfi-stock-tumbles-after-earnings-miss/cZ3HJWFRImB">WYFI Stock Tumbles Nearly 10% After Q4 Earnings Miss — What's Wall Street's Take?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

KODK Stock Crosses $10-Mark For First Time In Nearly 5 Years — Retail Cheers 'Kodak Moment'

Eastman Kodak shares surged more than 12% on Friday, garnering significant attention from retail investors.

Equity

<ul class="summary-bullets"><li>The company said the errors were identified in the consolidated financial statements for the year ended&nbsp;Dec.&nbsp;31, 2024 as well as out-of-period errors for all three quarters of 2025.</li><li>The majority of these errors relate to accounting for revenue, software development costs, and share-based payments.&nbsp;</li><li>TBRG said that the above-mentioned errors did not result in a material misstatement of its previously issued financial statements.</li></ul>TruBridge&nbsp;Inc.&nbsp;(TBRG), a leading provider of healthcare technology solutions for rural and community hospitals, announced on Monday&nbsp;that it has postponed its fourth-quarter (Q4) and year-end 2025 earnings release and conference call.TruBridge said that it requires additional time for the completion of its year-end audit procedures, and was therefore delaying its results previously scheduled for March 16, 2026.The company will issue a separate announcement confirming the date of the release of fourth quarter and year-end 2025 financial results,&nbsp;it said.&nbsp;Shares of the company declined more than 5% after the announcement.&nbsp;<h2 class="st-heading-2">Errors In Accounting</h2>TruBridge said that while conducting final procedures with the preparation of its financial statements for the fiscal year ended&nbsp;Dec. 31, 2025, errors were identified in the consolidated financial statements for the year ended&nbsp;Dec.&nbsp;31, 2024 as well as out-of-period errors in the condensed financial statements for the quarters ended March 31, June 30, and&nbsp;Sept. 30, 2025.The majority of these errors relate to accounting for revenue, software development costs, and share-based payments.&nbsp;TBRG said that the above-mentioned errors did not result in a material misstatement of its previously issued financial statements, and the errors are non-cash in nature, and do not impact company’s operations or liquidity.&nbsp;TruBridge expects to file the 2025 Form 10-K within the 15-day extension period granted by the&nbsp;U.S. Securities and Exchange Commission (SEC), as well as issue its&nbsp;Q4 and year-end 2025 financial results and hold its rescheduled earnings call by March 31, 2026.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around TBRG&nbsp;stock trended in ‘neutral territory’ amid ‘high’ message volume.&nbsp;Shares in the company have fallen 25% so far in 2026.&nbsp;

Shares of TruBridge have fallen 25% so far in 2026. 

Why Has TruBridge Delayed Its Planned Q4 Results?

TruBridge said that it requires additional time for the completion of its year-end audit procedures.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

CNVS Stock Surged 20% Today, Breaching 100-DMA For First Time Since August – Here’s What Triggered The Rally

The company announced the acquisition of ad-tech firm IndiCue for up to $40 million in total consideration.

<ul class="summary-bullets"><li>Prelude Therapeutics now anticipates dosing the first patient with PRT12396 by the second quarter of 2026.</li><li>The early stage trial will determine the safety, efficacy and pharmacokinetic profile of PRT12396.</li><li>The company said that the FDA’s clearance marks the first milestone in its focus on certain programs that it outlined in the last quarter.</li></ul> Shares of Prelude Therapeutics Incorporated (PRLD) closed 13% higher on Tuesday and edged up 2% after hours after the U.S. Food and Drug Administration (FDA) gave clearances to proceed with early-stage trials for its experimental drug PRT12396.PRT12396 is being developed for the treatment of patients with certain myeloproliferative neoplasms. Myeloproliferative neoplasms (MPNs) are a group of rare, slow-growing blood cancers where the bone marrow produces too many red blood cells, platelets, or certain white blood cells, often due to acquired genetic mutations, leading to symptoms like fatigue, itching, headaches, and bleeding or clotting issues.<h2 class="st-heading-2">Trial Design And Timeline</h2>Prelude Therapeutics <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/03/3231175/0/en/Prelude-Therapeutics-Receives-FDA-Clearance-of-Investigational-New-Drug-Application-IND-for-PRT12396-a-Mutant-selective-JAK2V617F-Inhibitor.html">anticipates</a> dosing the first patient with the drug by the second quarter of 2026. The company said that the FDA’s clearance marks the first milestone in its focus on certain programs that it outlined in the last quarter.“We look forward to advancing PRT12396 into the phase 1 study in patients with polycythemia vera and myelofibrosis in parallel,” said Kris Vaddi, Chief Executive Officer of Prelude. Both polycythemia vera and myelofibrosis are types of blood cancer.The early-stage trial will determine the safety, efficacy and pharmacokinetic profile of PRT12396.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PRLD stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.A Stocktwits user opined that the news might be a hint that the company is moving in the right direction.<stembedurl>https://www.stocktwits.com/Jaybird827/message/643826772</stembedurl>Another voiced optimism for the stock rising as high as $3.<stembedurl>https://www.stocktwits.com/moosegoose/message/643791216</stembedurl><a href="https://stocktwits.com/symbol/PRLD">PRLD stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-shares-garner-retail-attention-ahead-of-q4-earnings-report/cZb02YuR4mN">VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did PRLD Stock Surge 13% Today?

Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396. 

<ul class="summary-bullets"><li>Cantor Fitzgerald’s new price target on CABA represents over 1,000% potential upside to the stock’s closing price on Thursday.</li><li>The company said on Monday that data from across trials reinforce the potential of a single weight-based dose of Rese-cel to deliver durable, drug-free clinical responses across multiple autoimmune diseases.</li><li>Rese-cel is an investigational, autologous CAR-T cell therapy explicitly designed for the treatment of autoimmune diseases in rheumatology, neurology, and dermatology. &nbsp;</li></ul>Cantor Fitzgerald on Friday raised its price target on Cabaletta Bio (CABA) to $30 from $15 while keeping an ‘Overweight’ rating on the shares.The new price target represents over 1,000% potential upside to the stock’s closing price on Thursday.According to TheFly, the analyst noted that Auto-CAR-T is showing unprecedented and transformational efficacy in systemic sclerosis, and investors aren't appreciating the substantial unmet need.Scleroderma, also known as systemic sclerosis, is a group of autoimmune diseases that cause the hardening and tightening of the skin and connective tissues, and can also damage blood vessels and internal organs. It is characterized by the excessive buildup of collagen, which leads to fibrosis.<h2 class="st-heading-2">Cabaletta Presents Positive Data</h2>Cabaletta on Monday announced positive clinical data across trials evaluating Rese-cel. Rese-cel is an investigational, autologous CAR-T cell therapy explicitly designed for the treatment of autoimmune diseases in rheumatology, neurology, and dermatology. It is administered as a single, weight-based infusion to reset the immune system and achieve durable clinical responses without the need for chronic therapy.The company said that the data from the trials reinforce the potential of a single weight-based dose of Rese-cel to deliver durable, drug-free clinical responses across multiple autoimmune diseases.“We look forward to initiating the myositis registrational trial and anticipate alignment with FDA on the designs for lupus and systemic sclerosis this year,” said David J. Chang, Chief Medical Officer of Cabaletta, on Monday.While Myositis is a group of rare conditions characterized by muscle inflammation, Lupus is a chronic autoimmune disease where the body's immune system mistakenly attacks healthy tissues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CABA">CABA stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:621/60;" src="data:image/png;base64,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" width="621" height="60" alt="CABA's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Oct. 31, 2025 | Source: Stocktwits"><figcaption>CABA's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Oct. 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the company’s pipeline to generate substantial revenue in six years.<stembedurl>https://stocktwits.com/Bronco6970/message/634482351</stembedurl>CABA stock is up by 46% this year but has dropped 7% over the past 12 months. &nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pony-ai-stock-flips-between-gains-and-losses-after-key-shenzhen-permit/cLGqPQKR3U6">Pony AI Stock Flips Between Gains And Losses After Key Shenzhen Permit: Retail Expects Shares ‘Will Run Up In The Future’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cabaletta Bio logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock?

The analyst noted that Auto-CAR-T is showing unprecedented and transformational efficacy in systemic sclerosis, and investors aren't appreciating the substantial unmet need this represents. 

Small-Cap ETFs Rally in July: Will the Momentum Continue?

Small-cap ETFs like AVSC, XSVM, BBSC, SVAL and EES are soaring in July, fueled by rate cut hopes, deep discounts and sector rebounds.


Shares of Corvus Pharmaceuticals, Inc., fell in Tuesday's extended trading hours after the company posted financial results below Wall Street expectations, although retail traders remained optimistic.The pre-revenue biotech posted an adjusted fourth-quarter (Q4) loss of $0.18 per share, steeper than the expected $0.12 loss.&nbsp;Research and development expenses in the reported quarter rose to $6 million from $4 million a year earlier, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.R&amp;D expenses climbed to $19.4 million for the full year from $16.5 million in 2023."We continue to advance our selective ITK inhibitor, soquelitinib, in a range of diseases," said CEO Richard Miller.Preclinical data supports its potential in a range of conditions, including solid tumors, autoimmune disorders such as ALPS and systemic sclerosis, as well as inflammatory diseases like asthma and psoriasis.Corvus is nearing complete enrollment in the third cohort of its Phase 1 atopic dermatitis trial, while its Phase 3 trial in peripheral T-cell lymphoma (PTCL) is enrolling patients across multiple sites.&nbsp;The company recently launched a Phase 2 trial for ALPS and plans to initiate a solid tumor study in the third quarter of 2025.As of Dec. 31, 2024, Corvus held $52 million in cash, cash equivalents, and marketable securities, up from $27.1 million a year ago, which it expects to fund operations into the first quarter of 2026.On Stocktwits, sentiment for Corvus flipped into 'extremely bullish' territory from 'bearish' a day ago, accompanied by a 1,000% spike in message volume.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CRVS_sentiment_and_message_volume_as_of_March_25_png_2347150685.webp" alt="CRVS sentiment and message volume as of March 25.png" width="1318" height="302"><figcaption>CRVS sentiment and message volume as of March 25. | source: Stocktwits</figcaption></figure>One user was bullish after the company's chief executive said the full data for the first three cohorts of its atopic dermatitis trial would be presented at the Society for Investigative Dermatology (SID) Annual Meeting in San Diego in May.<stembedurl>https://stocktwits.com/WalterBean/message/609216709</stembedurl>Another retail watcher expects the stock to close above $4 on Wednesday.<stembedurl>https://stocktwits.com/tradingjunk321/message/609231445</stembedurl>Corvus stock is down more than 28% this year but has more than doubled over the past 12 months. According to Koyfin, out of the six analysts covering the stock on Wall Street, five rate it 'buy' and one rates it 'strong buy.'For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger

Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma. 

Verint Systems, Inc. ($VRNT), a customer experience automation company, announced fiscal year 2025 third-quarter results that exceeded expectations, thanks to strong artificial intelligence (AI) momentum. The company maintained its full-year guidance, sending its shares sharply higher on Thursday.The Melville, New York-based company reported third-quarter non-GAAP earnings per share (EPS) of $0.54, down from the $0.65 earned a year ago but exceeding the consensus estimate of $0.43.Revenue climbed 3% year-over-year to $224 million, above the average analysts’ estimate of $210.13 million. The revenue growth was 5% on a non-GAAP basis, as adjusted for the divestiture of the quality managed services business.Dan Bodner, Verint CEO, said, “We are pleased with our momentum in AI innovation and in customers reporting strong, tangible AI business outcomes with the Verint open platform.”“In Q3, we saw strong demand for AI business outcomes and our bundled SaaS revenue growth accelerated to 19% year-over-year.”Verint said its new software-as-a-service (SaaS) average contract value (ACV) bookings for new deals, excluding cloud conversions, increased 37% YoY in the third quarter.Gross margins expanded 70 basis points YoY due to the mix shift toward recurring revenue.The company maintained its 2025 revenue guidance of $933 million, +/- 2 percentage points and EPS outlook of $2.90. Analysts, on average, estimate the numbers to be $933.26 and $2.91, respectively.Verint also announced its latest AI-powered bot on the Veint platform on Thursday.&nbsp;CFO Grant Highlander said the company will showcase its AI differentiation at the upcoming investor day on January 14.&nbsp;“Investors will hear directly from our customers on AI business outcomes and we will review our financial model, including FYE26 guidance and our long-term model for monetizing AI,” he added.<figure class="image"><img style="aspect-ratio:643/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/vrnt_sentiment_8f1342b2c0.png" alt="vrnt-sentiment.png" width="643" height="137"><figcaption>VRNT sentiment and message volume December 5, 2024, premarket as of 11:26 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Stocktwits users are ‘extremely bullish’ (97/100) toward the stock, with sentiment improving from neutral a day ago. Message volume continues to be ‘extremely high.’At last check, Verint shares climbed 24.53% to $32.34. The stock has lost about 4% this year but has traded in the $21-$38 range.For updates and corrections email newsroom[at]stocktwits[dot]com.

Artificial Intelligence - Chatbot concept in neon style - stock photo

Verint Stock Soars On AI-Fueled Q3 Beat: Retail Sentiment Brightens

Verint highlighted the momentum in AI innovation and customers reporting strong, tangible AI business outcomes with its open platform.

Current Price	$67.79
Prev Close	$67.52
Open	$67.68
Dividend Yield	N/A
50-Day Moving Average	$63.90
Beta	N/A
Avg. Volume	155,955.46
PE Ratio	N/A

52-Week High	$68.55
52-Week Low	$45.55
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

AVSC
American Century ETF Trust - Avantis U.S Small Cap Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AVSC News

AVSCAmerican Century ETF Trust - Avantis U.S Small Cap Equity ETF